The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Botanix Pharmaceuticals Ltd stock forecast from 0 analysts, the average analyst target price for Botanix Pharmaceuticals Ltd is not available over the next 12 months. Botanix Pharmaceuticals Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Botanix Pharmaceuticals Ltd is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Botanix Pharmaceuticals Ltd’s stock price was AUD 0.37. Botanix Pharmaceuticals Ltd’s stock price has changed by +0.00% over the past week, +7.25% over the past month and +174.07% over the last year.
No recent analyst target price found for Botanix Pharmaceuticals Ltd
No recent average analyst rating found for Botanix Pharmaceuticals Ltd
Company Overview Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia. Address: D2, 661 Newcastle Street, Leederville, WA, Australia, 6007 Read Less
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a dru...Read More
Frequently Asked Questions About Botanix Pharmaceuticals Ltd (BOT:AU) Stock
Stock Target Advisor's fundamental analysis for Botanix Pharmaceuticals Ltd's stock is Slightly Bearish.
Unfortunately we do not have enough data on BOT:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BOT:AU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BOT:AU's stock to indicate if its overvalued.
The last closing price of BOT:AU's stock was AUD 0.37.
The most recent market capitalization for BOT:AU is AUD 0.67B.
Unfortunately we do not have enough analyst data on BOT:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Botanix Pharmaceuticals Ltd's stock.
As per our most recent records Botanix Pharmaceuticals Ltd has 0 Employees.
Botanix Pharmaceuticals Ltd's registered address is D2, 661 Newcastle Street, Leederville, WA, Australia, 6007.
You can get more information about it from Botanix Pharmaceuticals Ltd's website at https://www.botanixpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BOT:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
